TODAY'S HEADLINES

Why new bladder cancer drug is novel

This drug, which was recently granted accelerated approval by FDA, is the first treatment for bladder cancer that utilizes the body's immune system. Read more

Opdivo snags two new cancer approvals

Nivolumab (Opdivo, Bristol-Myers Squibb) recently received two new approvals from FDA to treat two different cancers. Find out which cancers

CONTINUING PHARMACY EDUCATION

Keep your patients moving: An overview of treatment options for constipation

This month's CE activity, "Keep your patient moving: An overview of treatment options for constipation," is open for pharmacists and pharmacy technicians.
The goal of this program is to assist pharmacists and pharmacy technicians in their understanding of the role of linaclotide, lubiprostone, methylnaltrexone, and naloxegol in the treatment of constipation after conventional nonpharmacologic interventions and conventional laxatives such as bulking agents, osmotic laxatives, and stimulant laxatives have failed.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

Spike in drug shortages raises alarm

By April, 2016, more than 300 drugs were in short supply. Find out how the severe drug shortages are impacting hospitals – especially emergency departments. Read more

June 01, 2016

Related Articles

Faster FDA approvals lead to cancer drug boom

FDA expands Opdivo use for metastatic melanoma